BioCryst Pharmaceuticals, Inc.
Prodrugs of kallikrein inhibitors

Last updated:

Abstract:

Disclosed are compounds of formula I, II, and III, and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein. Also provided are pharmaceutical compositions comprising such a compound, and methods involving use of the compounds and compositions in the treatment and prevention of acquired or hereditary angioedema, or other diseases and conditions characterized by aberrant kallikrein activity. ##STR00001##

Status:
Grant
Type:

Utility

Filling date:

27 Oct 2017

Issue date:

1 Sep 2020